Association between the 21-gene recurrence score (RS) and benefit from adjuvant paclitaxel (Pac) in node-positive (N plus ), ER-positive breast cancer patients (pts): Results from NSABP B-28

被引：4
|
作者：
Mamounas, E. P.
Tang, G.
Paik, S.
Baehner, F. L.
Liu, Q.
Jeong, J-H
Kim, S-R
Butler, S. M.
Jamshidian, F.
Cherbavaz, D. B.
Sing, A. P.
Shak, S.
Julian, T. B.
Lembersky, B. C.
Wickerham, D. L.
Costantino, J. P.
Wolmark, N.
机构：
[1] Natl Surg Adjuvant Breast & Bowel Project, Operat Ctr, Pittsburgh, PA USA
[2] Natl Surg Adjuvant Breast & Bowel Project, Biostat Ctr, Pittsburgh, PA USA
[3] Aultman Hosp, Canton, OH USA
[4] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA 15260 USA
[5] Genom Hlth Inc, Redwood City, CA USA
[6] Allegheny Gen Hosp, Allegheny Canc Ctr, Pittsburgh, PA 15212 USA
[7] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15260 USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/0008-5472.SABCS12-S1-10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
S1-10
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Use across Michigan of the 21-gene recurrence score (RS) assay in lymph node positive patients with breast cancer
    Henry, N. L.
    Ali, H.
    Braun, T.
    Munir, K.
    Silver, S. M.
    Griggs, J. J.
    Breslin, T. M.
    Gorski, D. H.
    CANCER RESEARCH, 2016, 76
  • [22] The 21-Gene Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer Treated on SWOG S8814
    Woodward, W. A.
    Barlow, W. E.
    Jagsi, R.
    Buchholz, T. A.
    Shak, S.
    Baehner, F.
    Yoshizawa, C. N.
    Whelan, T. J.
    Davidson, N. E.
    Ingle, J. N.
    King, T. A.
    Ravdin, P. M.
    Osborne, C. K.
    Tripathy, D.
    Livingston, R. B.
    Gralow, J. R.
    Hortobagyi, G. N.
    Hayes, D. F.
    Albain, K. S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S146 - S146
  • [23] Prognostic value of the 21-gene recurrence score in ER-positive,HER2-negative, node-positive breast cancer was similar in node-negative diseases: a single-center study of 800 patients
    Jiayi Wu
    Weiqi Gao
    Xiaosong Chen
    Chunxiao Fei
    Lin Lin
    Weiguo Chen
    Ou Huang
    Siji Zhu
    Jianrong He
    Yafen Li
    Li Zhu
    Kunwei Shen
    Frontiers of Medicine, 2021, 15 (04) : 621 - 628
  • [24] Prognostic value of the 21-gene recurrence score in ER-positive, HER2-negative, node-positive breast cancer was similar in node-negative diseases: a single-center study of 800 patients
    Jiayi Wu
    Weiqi Gao
    Xiaosong Chen
    Chunxiao Fei
    Lin Lin
    Weiguo Chen
    Ou Huang
    Siji Zhu
    Jianrong He
    Yafen Li
    Li Zhu
    Kunwei Shen
    Frontiers of Medicine, 2021, 15 : 621 - 628
  • [25] Prognostic value of the 21-gene recurrence score in ER-positive, HER2-negative, node-positive breast cancer was similar in node-negative diseases: a single-center study of 800 patients
    Wu, Jiayi
    Gao, Weiqi
    Chen, Xiaosong
    Fei, Chunxiao
    Lin, Lin
    Chen, Weiguo
    Huang, Ou
    Zhu, Siji
    He, Jianrong
    Li, Yafen
    Zhu, Li
    Shen, Kunwei
    FRONTIERS OF MEDICINE, 2021, 15 (04) : 621 - 628
  • [26] A COST-CONSEQUENCE MODEL OF USING THE 21-GENE BREAST RECURRENCE SCORE ASSAY TO IDENTIFY PATIENTS WITH EARLY-STAGE NODE-POSITIVE BREAST CANCER WHO BENEFIT FROM ADJUVANT CHEMOTHERAPY IN THE NETHERLANDS
    Machielsen, P.
    de Jongh, F. E.
    Drost, P.
    Simons, M.
    Spoorendonk, J. A.
    VALUE IN HEALTH, 2022, 25 (12) : S63 - S63
  • [27] Clinical relevance of the 21-gene Recurrence Score® assay in treatment decisions for patients with node-positive breast cancer in the genomic era
    Mamounas, Eleftherios P.
    Russell, Christy A.
    Lau, Anna
    Turner, Michelle P.
    Albain, Kathy S.
    NPJ BREAST CANCER, 2018, 4
  • [28] Physician Survey of the Effect of the 21-Gene Recurrence Score Assay Results on Treatment Recommendations for Patients With Lymph Node-Positive, Estrogen Receptor-Positive Breast Cancer
    Oratz, Ruth
    Kim, Benjamin
    Chao, Calvin
    Skrzypczak, Stanley
    Ory, Caron
    Bugarini, Roberto
    Broder, Michael
    JOURNAL OF ONCOLOGY PRACTICE, 2011, 7 (02) : 94 - +
  • [29] Clinical relevance of the 21-gene Recurrence Score® assay in treatment decisions for patients with node-positive breast cancer in the genomic era
    Eleftherios P. Mamounas
    Christy A. Russell
    Anna Lau
    Michelle P. Turner
    Kathy S. Albain
    npj Breast Cancer, 4
  • [30] Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada
    Torres, Sofia
    Trudeau, Maureen
    Gandhi, Sonal
    Warner, Ellen
    Verma, Sunil
    Pritchard, Kathleen I.
    Petrella, Teresa
    Hew-Shue, Mark
    Chao, Calvin
    Eisen, Andrea
    ONCOLOGIST, 2018, 23 (07): : 768 - 775
12345